These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20607359)

  • 1. A fusion fragment from Flt-1 and KDR, acted as VEGF decoy receptor and exhibited anti-tumor function.
    Li ZL; Yao XJ; Liu WF; Chen GJ
    Biotechnol Lett; 2010 Nov; 32(11):1609-13. PubMed ID: 20607359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
    Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
    Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells.
    Ahmed A; Dunk C; Kniss D; Wilkes M
    Lab Invest; 1997 Jun; 76(6):779-91. PubMed ID: 9194854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
    Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
    Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
    Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of vascular endothelial growth factor and its receptors in the porcine corpus luteum during the estrous cycle and early pregnancy.
    Kaczmarek MM; Kowalczyk AE; Waclawik A; Schams D; Ziecik AJ
    Mol Reprod Dev; 2007 Jun; 74(6):730-9. PubMed ID: 17120307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coexpression of vascular endothelial growth factor and its receptors in human tumor cell lines].
    Fu JX; Wang W; Bai X; Wang L; Zhu ZL; Chen ZX; Ruan CG
    Ai Zheng; 2002 Nov; 21(11):1217-21. PubMed ID: 12526219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and function identification of extracellular domain 3 of human vascular endothelial growth factor receptor KDR].
    Zhang J; Zhang Y; Li H; Chen W; Zhang T; Wang M
    Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1962-7. PubMed ID: 19256346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
    Barleon B; Siemeister G; Martiny-Baron G; Weindel K; Herzog C; Marmé D
    Cancer Res; 1997 Dec; 57(23):5421-5. PubMed ID: 9393770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of monoclonal antibody against extracellular domain III of vascular endothelial growth factor receptor KDR on proliferation of vascular endothelial cells].
    Li R; Xiong DS; Shao XF; Xu YF; Zhu ZP; Yang CZ
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):209-12. PubMed ID: 15949417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma].
    Sha D; He YJ
    Ai Zheng; 2006 Feb; 25(2):229-34. PubMed ID: 16480593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.
    Davis-Smyth T; Chen H; Park J; Presta LG; Ferrara N
    EMBO J; 1996 Sep; 15(18):4919-27. PubMed ID: 8890165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of vascular endothelial growth factor and its receptors, flt-1 and kinase insert domain-containing receptor in normal human endometrium during menstrual cycle].
    Wang H; Chen G
    Zhonghua Fu Chan Ke Za Zhi; 2002 Dec; 37(12):729-32. PubMed ID: 12622916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the differential activation of vascular endothelial growth factor (VEGF) receptors.
    Horta BA; Sodero AC; de Alencastro RB
    J Mol Graph Model; 2009 Oct; 28(3):287-96. PubMed ID: 19734078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.